FEATURED NEWS Home — Back Bay Life Science Advisors

Back Bay Advised Caladrius Biosciences on Merger with Cend Therapeutics

Back Bay Life Science Advisors’ investment banking and strategy teams announced their role in the deal between Caladrius Biosciences, now called Lisata Therapeutics, and Cend Therapeutics

Back Bay Transaction NewsBack Bay Life Science AdvisorsSeptember 19, 2022Transactions, Investment Banking, Mergers

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

Press Release, Client NewsBack Bay Life Science AdvisorsSeptember 15, 2022Merger, Oncology, Biopharma, Investment Banking

Inflation Reduction Act: Unprecedented Changes to Medicare Prescription Drug Pricing

Back Bay Life Science AdvisorsAugust 11, 2022

Cell and Gene Therapy in Canada - Insights Magazine

Back Bay in the NewsBack Bay Life Science AdvisorsJune 2, 2022Cell Therapy, Drug Development, Biopharma, Funding, Partnering, Canada

From Drug Target Inhibition to Degradation: a TACtical Strategy - Nature Biopharma Dealmakers

Back Bay in the NewsBack Bay Life Science AdvisorsJune 2, 2022IPOs, VC, Drug Development, Investment Banking

Inefficient Markets: Public Market Dislocations and Negative Biotech Enterprise Values

BlogInvestment Banking TeamMay 31, 2022BioPharma, IPO, Investing

Biopharma Companies Don’t Need to Be Public to Survive

BlogInvestment Banking TeamApril 14, 2022BioPharma, IPO, Investing

A Paradigm Shift in Medical Technology

Investment Banking UpdateInvestment Banking TeamMarch 14, 2022Investment, Medtech, Digital Health, Healthtech

Back Bay Associate Named Consulting Magazine’s Rising Star for Excellence in Financial Consulting

Back Bay in the News, Awards and RankingsInvestment Banking TeamFebruary 28, 2022Investment Banking, Consulting Awards

Back Bay Life Science Advisors Ranked Among Best Boutique Consulting Firms

Back Bay ranked Top Boutique Consulting Firm 2022

Awards and RankingsBack Bay Life Science AdvisorsFebruary 15, 2022Best Consulting Firm Ranking, Life Science Jobs

Back Bay in Cell & Gene: Shining Light on the Commercial Potential of Optogenetic Therapies

Back Bay Life Science Advisors examines the commercial and clinical potential of optogenetic therapies from ophthalmology diseases, and oncology to chronic pain and more.

BlogBack Bay Life Science AdvisorsFebruary 3, 2022Neurology, Optogenetics, Oncology

With Biotech Public Valuations Down, Look to Alternative Strategies to Enhance Company Value

BlogBack Bay Life Science AdvisorsJanuary 31, 2022Valuation, Investment, M&A, Investment Banking

Back Bay in Wall Street Journal, Pro Venture Capital: Medical-Device IPOs, Acquisitions Jumped in 2021

Media CoverageBack Bay Life Science AdvisorsJanuary 15, 2022Investing, Medical Device, IPOs, M&A

Trends, Opportunities, and Outlooks for Investment in the US Biotech Market

WebinarBack Bay Life Science AdvisorsJanuary 4, 2022Biotech, Biotech Investment, Canada

Investment Banking Spotlight: GE, Johnson & Johnson, Philips, Siemens: Restructurings = Accelerating Focus and Investment

BlogInvestment Banking TeamDecember 14, 2021Investment Banking, Restructuring, Life Science Financing

Outsourced Pharma: The Pharmacological Treatment Pipeline For Traumatic Brain Injury

BlogBack Bay Life Science AdvisorsDecember 13, 2021Pharmaceutical Development, Neurology, Drug Pipeline, FDA

Companies and Themes to Watch at ASH 2021

BlogBack Bay Life Science AdvisorsDecember 9, 2021Cell Therapy, Oncology, hematology, Blood

Back Bay Life Science Advisors Announces Expansion into Canada with Opening of Toronto Office

Back Bay NewsBack Bay Life Science AdvisorsNovember 29, 2021MaRS Discovery DistrictBack Bay Growth

Cell and Gene Therapy Investment Trends [Podcast]

PodcastBack Bay Life Science AdvisorsNovember 22, 2021Cell Therapy, Gene Therapy, Investment, Industry Insights

Med Device Online: An Overview of The Remote Patient Monitoring Device & Telehealth Market

Back Bay in the NewsBack Bay Life Science AdvisorsNovember 1, 2021Medtech investment, Remote Patient Monitoring, Investment, Life Science Deals